EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Understanding the molecular mechanisms of statin pleiotropic effects

Charles A German, James K Liao

Archives of Toxicology · 2023-06 · 97 (6) · 1529-1545

DOI: 10.1007/s00204-023-03492-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archives of Toxicology, online erschienen am 21.04.2023. Verfasst von Charles A German und 1 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL, USA. cagerman@bsd.uchicago.edu. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Thrombosis. Die Arbeit wurde bisher 149-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Statins represent the cornerstone of pharmacotherapy for the prevention of atherosclerotic cardiovascular disease. These medications not only reduce low-density lipoprotein cholesterol (LDL-C) via inhibition of 3-hydroxy-3-methylglutarate attached to CoA reductase, the key rate-limiting step in the cholesterol biosynthetic pathway, but also upregulate expression of the low-density lipoprotein receptor, improving serum clearance. Given LDL-C is a causal risk factor for the development of atherosclerosis, these complementary mechanisms largely explain why statin therapy leads to reductions in major adverse cardiovascular events. However, decades of basic and clinical research have suggested that statins may exert other effects independent of LDL-C lowering, termed pleiotropic effects, which have become a topic of debate among the scientific community. While some literature suggests statins may improve plaque stability, reduce inflammation and thrombosis, decrease oxidative stress, and improve endothelial function and vascular tone, other studies have suggested potential harmful pleiotropic effects related to increased risk of muscle-related side effects, diabetes, hemorrhagic stroke, and cognitive decline. Furthermore, the introduction of newer, non-statin LDL-C lowering therapies, including ezetimibe, proprotein convertase subtilisin/Kexin Type 9, and bempedoic acid, have challenged the statin pleiotropy theory. This review aims to provide a historical background on the development of statins, explore the mechanistic underpinnings of statin pleiotropy, review the available literature, and provide up to date examples that suggest statins may exert effects outside of LDL-C lowering and the cardiovascular system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsThrombosisHumansCholesterol, LDLHypolipidemic AgentsRisk Factors

Stichwörter der Autor:innen

AtherosclerosisCardiovascular diseaseCholesterolLDLStatin

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLHypolipidemic Agents

Autor:innen und Institutionen

  • Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL, USA. cagerman@bsd.uchicago.edu.
  • Department of Medicine, University of Arizona, Tucson, AZ, USA.

Zitieren

APA

German, C. A., & Liao, J. K. (2023). Understanding the molecular mechanisms of statin pleiotropic effects. Archives of Toxicology, 97(6), 1529-1545. https://doi.org/10.1007/s00204-023-03492-6

Vancouver

German CA, Liao JK. Understanding the molecular mechanisms of statin pleiotropic effects. Archives of Toxicology. 2023;97(6):1529-1545. doi:10.1007/s00204-023-03492-6

BibTeX
@article{German2023,
  author = {German, Charles A and Liao, James K},
  title = {Understanding the molecular mechanisms of statin pleiotropic effects},
  journal = {Archives of Toxicology},
  year = {2023},
  volume = {97},
  number = {6},
  pages = {1529--1545},
  doi = {10.1007/s00204-023-03492-6}
}
Kostenlos starten →